These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28434174)

  • 41. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
    Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
    Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer.
    Yang YR; Zang SZ; Zhong CL; Li YX; Zhao SS; Feng XJ
    Int J Clin Exp Pathol; 2014; 7(10):6929-35. PubMed ID: 25400777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
    Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
    Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
    Sandoval J; Mendez-Gonzalez J; Nadal E; Chen G; Carmona FJ; Sayols S; Moran S; Heyn H; Vizoso M; Gomez A; Sanchez-Cespedes M; Assenov Y; Müller F; Bock C; Taron M; Mora J; Muscarella LA; Liloglou T; Davies M; Pollan M; Pajares MJ; Torre W; Montuenga LM; Brambilla E; Field JK; Roz L; Lo Iacono M; Scagliotti GV; Rosell R; Beer DG; Esteller M
    J Clin Oncol; 2013 Nov; 31(32):4140-7. PubMed ID: 24081945
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.
    Yao F; Zhou W; Zhong C; Fang W
    Tumour Biol; 2015 Sep; 36(10):7873-9. PubMed ID: 25946971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aberrant Hypermethylation at Sites -86 to 226 of DAB2 Gene in Non-Small Cell Lung Cancer.
    Li C; Chen J; Chen T; Xu Z; Xu C; Ding C; Wang Y; Lei Z; Zhang HT; Zhao J
    Am J Med Sci; 2015 May; 349(5):425-31. PubMed ID: 25719979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.
    Xue Q; Zhou Y; Wan C; Lv L; Chen B; Cao X; Ju G; Huang Y; Ni R; Mao G
    Exp Mol Pathol; 2013 Dec; 95(3):313-8. PubMed ID: 23920144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression level and methylation status of three tumor suppressor genes, DLEC1, ITGA9 and MLH1, in non-small cell lung cancer.
    Pastuszak-Lewandoska D; Kordiak J; Antczak A; Migdalska-Sęk M; Czarnecka KH; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska-Senderowska D; Brzeziańska-Lasota E
    Med Oncol; 2016 Jul; 33(7):75. PubMed ID: 27287342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients.
    Andjelkovic T; Bankovic J; Milosevic Z; Stojsic J; Milinkovic V; Pesic M; Ruzdijic S; Tanic N
    Cancer Biomark; 2011-2012; 10(6):277-86. PubMed ID: 22820083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Expression of LATS mRNA in mantle cell lymphoma and its clinical significance].
    Yu Z; Yi S; Zhang Y; Li Z; Qiu L
    Zhonghua Yi Xue Za Zhi; 2015 Oct; 95(40):3285-8. PubMed ID: 26815349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of high expression levels of STK39 in the growth, migration and invasion of non-small cell type lung cancer cells.
    Li Z; Zhu W; Xiong L; Yu X; Chen X; Lin Q
    Oncotarget; 2016 Sep; 7(38):61366-61377. PubMed ID: 27542260
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
    Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
    Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
    Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methylation‑associated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma.
    Chen KH; He J; Wang DL; Cao JJ; Li MC; Zhao XM; Sheng X; Li WB; Liu WJ
    Int J Oncol; 2014 Dec; 45(6):2511-21. PubMed ID: 25270913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
    Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
    Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of LATS transcriptional targets in HeLa cells using whole human genome oligonucleotide microarray.
    Visser S; Yang X
    Gene; 2010 Jan; 449(1-2):22-9. PubMed ID: 19799973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer.
    Liu YZ; Yang H; Cao J; Jiang YY; Hao JJ; Xu X; Cai Y; Wang MR
    Sci Rep; 2016 Apr; 6():24786. PubMed ID: 27098511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LATS tumor suppressor: a new governor of cellular homeostasis.
    Visser S; Yang X
    Cell Cycle; 2010 Oct; 9(19):3892-903. PubMed ID: 20935475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.